FindTrial
Sign In

Naratriptan

DRUG7 trials

Sponsors

UMC Utrecht, GlaxoSmithKline, Ache Laboratorios Farmaceuticos S.A., Fayoum University Hospitals

Conditions

AnaesthesiaAntisocial Personality DisorderHeadacheImpulse Regulation DisorderIntermittent Explosive DisorderMigraineMigraine DisordersPsychotic Disorders

Phase 3

Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine
WithdrawnNCT01390324
Ache Laboratorios Farmaceuticos S.A.Headache, Migraine
Start: 2011-12-31End: 2012-03-31Updated: 2016-10-19
Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine.
WithdrawnNCT01726920
Ache Laboratorios Farmaceuticos S.A.Headache, Migraine
Start: 2014-07-31Updated: 2016-03-16

Phase 4

Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order
TerminatedNCT00282165
UMC UtrechtAntisocial Personality Disorder, Impulse Regulation Disorder, Intermittent Explosive Disorder +1
Start: 2006-11-30End: 2012-12-31Updated: 2015-01-26
Comparison between the Effect of Sumatriptan versus Naratriptan in Treatment of Post-dural Puncture Headache in Obstetric patients. A Randomized Controlled Trial.
Active, not recruitingPACTR201901888984937
Fayoum University HospitalsAnaesthesia
Start: 2017-03-01Target: 189Updated: 2026-08-03

Unknown Phase

Sumatriptan and Naratriptan Pregnancy Registry
CompletedNCT01059604
GlaxoSmithKlineMigraine Disorders
Start: 2001-12-31End: 2013-04-30Updated: 2014-11-03
Special Drug Use Investigation for AMERGE® Tablet (Long-term)
CompletedNCT01332383
GlaxoSmithKlineMigraine Disorders
Start: 2009-05-31End: 2013-10-31Updated: 2015-08-13
Drug Use Investigation for AMERGE (Naratriptan Hydrochloride) Tablet
CompletedNCT01376193
GlaxoSmithKlineMigraine Disorders
Start: 2009-04-30End: 2011-10-31Updated: 2013-05-20